Adcendo aps is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (adcs).
Location: Denmark, Capital Region of Denmark, Copenhagen
Member count: 1-10
Total raised: $61.859421M
Investors 2
| Date | Name | Website |
| 29.04.2021 | Gilde Heal... | gildehealt... |
| - | Ysios Capi... | ysioscapit... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 30.04.2021 | Series A | $61.859421... | Ysios Capi... | healthcap.... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 30.04.2021 | Adcendo raises EUR 51 Million in Series A Financing to Advan... | Copenhagen, Denmark, 29 April 2021 – Adcendo, a biotech company developing antibody-drug conjugates ... | healthcap.... |
| 29.04.2021 | Ysios Capital leads a €51M round in Adcendo, also followed u... | ADCENDO RAISES €51 MILLION IN SERIES A FINANCING TO ADVANCE NOVEL ANTIBODY-DRUG CONJUGATES FOR TREAT... | webcapital... |
| 29.04.2021 | Adcendo Raises EUR 51M in Series A Financing | Adcendo, a Copenhagen, Denmark-based biotech company which is developing antibody-drug conjugates (A... | finsmes.co... |
| 29.04.2021 | Adcendo raises €51M series A round to pursue 'ideal' ADC tar... | Adcendo has raised a €51 million ($62 million) series A round to develop antibody-drug conjugates (A... | fiercebiot... |